Literature DB >> 11013800

Status epilepticus. Current concepts and management.

E Starreveld1, A A Starreveld.   

Abstract

OBJECTIVE: To inform primary care physicians about current issues around generalized convulsive status epilepticus (GCSE) emphasizing definition, pathophysiology, treatment, and prognosis. QUALITY OF EVIDENCE: MEDLINE (1994 to 1999) provided 479 references using the MeSH terms "status epilepticus" and "treatment." From these we selected 30 English-language articles covering clinical aspects, treatment, and animal research. Key source documents from previous years and information from modern textbooks and recent symposia were also included. MAIN MESSAGE: Generalized convulsive status epilepticus continues to be a medical emergency with high morbidity and mortality. It must be managed promptly and effectively. The operational definition of GCSE is a seizure that lasts longer than 5 minutes or two or more seizures between which patients do not recover. Main differential diagnosis is nonepileptic status. Intravenous therapy with combined lorazepam and phenytoin is the initial treatment of choice. Other preferred medications are diazepam, midazolam, and propofol. Some of these medications should be considered before arrival at hospital. Prognosis of GCSE is determined by underlying cause, delay in adequate treatment, and comorbidity. Patients with GCSE lasting longer than 30 minutes require intensive care and electroencephalogram monitoring.
CONCLUSION: Intravenous lorazepam and phenytoin are currently the most effective drugs for initial management of GCSE. Timely administration of antiepileptic medication can prevent development of GCSE in some patients with known epilepsy. Main differential diagnosis is nonepileptic status.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11013800      PMCID: PMC2145029     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  24 in total

Review 1.  Midazolam: a review of therapeutic uses and toxicity.

Authors:  S P Nordt; R F Clark
Journal:  J Emerg Med       Date:  1997 May-Jun       Impact factor: 1.484

Review 2.  The epidemiology and management of status epilepticus.

Authors:  M C Walker
Journal:  Curr Opin Neurol       Date:  1998-04       Impact factor: 5.710

Review 3.  Status epilepticus.

Authors:  D H Lowenstein; B K Alldredge
Journal:  N Engl J Med       Date:  1998-04-02       Impact factor: 91.245

4.  The effects of seizures on the brain.

Authors:  M W Lynch; P A Rutecki; T P Sutula
Journal:  Curr Opin Neurol       Date:  1996-04       Impact factor: 5.710

5.  Nasal benzodiazepines for management of acute childhood seizures?

Authors:  S J Wallace
Journal:  Lancet       Date:  1997-01-25       Impact factor: 79.321

6.  Short-term mortality after a first episode of status epilepticus.

Authors:  G Logroscino; D C Hesdorffer; G Cascino; J F Annegers; W A Hauser
Journal:  Epilepsia       Date:  1997-12       Impact factor: 5.864

7.  Intranasal midazolam in patients with status epilepticus.

Authors:  J L Kendall; M Reynolds; R Goldberg
Journal:  Ann Emerg Med       Date:  1997-03       Impact factor: 5.721

8.  A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group.

Authors:  D M Treiman; P D Meyers; N Y Walton; J F Collins; C Colling; A J Rowan; A Handforth; E Faught; V P Calabrese; B M Uthman; R E Ramsay; M B Mamdani
Journal:  N Engl J Med       Date:  1998-09-17       Impact factor: 91.245

9.  Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus.

Authors:  R J DeLorenzo; E J Waterhouse; A R Towne; J G Boggs; D Ko; G A DeLorenzo; A Brown; L Garnett
Journal:  Epilepsia       Date:  1998-08       Impact factor: 5.864

10.  Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin.

Authors:  T J O'Brien; G D Cascino; E L So; D R Hanna
Journal:  Neurology       Date:  1998-10       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.